Ganciclovir Injection, Solution
Product Images NDC 51817-171

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Ganciclovir (NDC 51817-171). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pharmascience Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Box Label 1

Flat packaging label for Ganciclovir Injection, 500 mg/10 mL (50 mg/mL) intravenous infusion solution by Pharmascience Inc. The label includes usage directions, warnings stating it is a cytotoxic agent, storage conditions, and that it is sterile, nonpyrogenic, and preservative-free. The package contains one 10 mL single-dose vial. The label features the NDC 51817-589-02 and manufacturer address in Candiac, Canada.*

FDA Label Image

Box Label 25

Packaging label for Ganciclovir Injection 500 mg/10 mL (50 mg/mL) solution for intravenous use by Pharmascience Inc. The label states it contains 25 single-dose vials, sterile and preservative-free. Storage instructions and caution for intravenous infusion use are included. A barcode and lot-specific information area are also visible.*

FDA Label Image

Chemical Structure Of Ganciclovir Sodium And Ganciclovir (Ganciclovir Image 1 Chemical Structure)

Chemical structure diagrams of ganciclovir sodium and ganciclovir are shown. The image includes molecular formulas (C9H12N5NaO4 for ganciclovir sodium and C9H13N5O4 for ganciclovir) and molecular weights (277.22 and 255.23 respectively).*

FDA Label Image

Figure 1 Trial Icm 1653: Time To Progression Of Cmv Retinitis (Ganciclovir Image 2 Icm 1653)

A line graph titled 'ICM 1653: Time to Progression of CMV Retinitis' showing proportion without progression over time from start of maintenance therapy in days. The graph compares intravenous (IV) and oral administration, with lines representing the proportion of patients without progression declining over approximately 150 days.*

FDA Label Image

Figure 2 Trial Icm 1774: Time To Progression Of Cmv Retinitis (Ganciclovir Image 3 Icm 1774)

A line graph titled 'ICM 1774: Time to Progression of CMV Retinitis' showing the proportion without progression over time from the start of maintenance therapy in days. Two lines compare intravenous (IV) and oral routes, with the IV group maintaining a higher proportion without progression over 120 days.*

FDA Label Image

Figure 3 Trial Avi 034: Time To Progression Of Retinitis (Ganciclovir Image 4 Avi 034)

A line graph titled 'AVI 034: Time to Progression of CMV Retinitis' displaying the proportion of patients without progression over time from start of maintenance therapy in days. Two lines represent intravenous (IV) treatment and oral treatment, showing the change in progression from 0 to 150 days.*

FDA Label Image

Vial Label

Ganciclovir Injection 500 mg/10 mL (50 mg/mL) vial label from Pharmascience Inc. This sterile, nonpyrogenic, preservative-free intravenous solution contains ganciclovir sodium equivalent to 500 mg of ganciclovir. The container closure is free of natural rubber latex. The label includes usage instructions cautioning cytotoxicity and carcinogen risk, storage conditions, and a barcode with NDC 51817-171-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.